ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.4012
-0.18%
Brent Oil
84.665
-0.04%
Bitcoin
65,711.43
1.15%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) Noticias

LXRX Lexicon Pharmaceuticals Inc

1.75
0.00 (0.00%)
Pre Mercado
Última actualización: 03:11:50
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lexicon Pharmaceuticals Inc LXRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 1.75 03:11:50
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.75
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
19/6/202407:00GLOBEData From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211..
18/6/202407:00GLOBEAnalysis of INPEFA® (Sotagliflozin) Cost-Effectiveness..
14/6/202407:00GLOBEFindings on the Burdens of Diabetic Peripheral Neuropathic..
29/5/202406:30GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
15/5/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
14/5/202416:05EDGAR2Form SC 13D/A - General statement of acquisition of..
14/5/202406:00GLOBENew Post-Hoc Analysis of Pooled Phase 3 Data Shows That..
13/5/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202415:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202416:14EDGAR2Form S-3/A - Registration statement under Securities Act of..
10/5/202415:15EDGAR2Form 8-K - Current report
09/5/202406:30GLOBELexicon Pharmaceuticals to Participate in the Bank of..
02/5/202415:05GLOBELexicon Pharmaceuticals Reports First Quarter 2024 Financial..
29/4/202408:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29/4/202406:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18/4/202407:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03/4/202407:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25/3/202408:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12/3/202407:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
11/3/202415:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11/3/202406:26EDGAR2Form 8-K - Current report
11/3/202406:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11/3/202406:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11/3/202406:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
29/2/202415:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202406:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
29/12/202316:29EDGAR2Form 8-K - Current report
29/12/202316:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/12/202315:04EDGAR2Form 8-K - Current report
21/12/202315:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30/11/202306:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22/11/202306:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
17/11/202315:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202316:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202313:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
10/11/202315:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
08/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

NASDAQ
LXRX
Lexicon Pharmaceuticals
COIN
TIPPETH
Tipcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados